-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical News, September 1st, August 30th, the official website of the State Food and Drug Administration showed that Tonghua Dongbao Pharmaceutical was approved for imitation of Sitagliptin phosphate tablets for production in Category 4, and was deemed to have been reviewed
.
According to data from Menet.
com, in 2020, the total sales of sitagliptin phosphate tablets at the terminals of China's public medical institutions and the terminals of physical pharmacies in China's cities will exceed 1.
5 billion yuan, and only one company from Merck & Co.
is selling them
.
On August 30, 2021, the drug approval document pending information is released.
Sitagliptin phosphate tablets were developed by Merck.
It is a potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor.
A new type of oral anti-hyperglycemic drug based on the mechanism of incretin hormone is used to improve the blood glucose control of patients with type 2 diabetes
.
Sales of sitagliptin phosphate tablets in Chinese public medical institutions and Chinese urban physical pharmacies (unit: 100 million yuan) Source: Minet.
com database Minet.
com data shows that in recent years, it has been used in urban public hospitals , county-level public hospitals, urban community centers and township hospitals (referred to as the Chinese public medical institutions) terminal and the Chinese cities entity pharmacy sitagliptin phosphate tablets terminal sales of rapid growth, in 2020 a total of more than 1.
5 billion yuan, Merck only one company in sales
.
Sitagliptin phosphate tablets manufacturers include Merck, CSPC Ouyi Pharmaceutical, CP Tianqing Pharmaceutical Group, among which CSPC Ouyi Pharmaceutical, CP Tianqing Pharmaceutical Group, Guangdong Dongyang Sunshine Pharmaceutical Six domestic pharmaceutical companies, including Tonghua Dongbao Pharmaceutical Co.
, Ltd.
, have been approved for imitation of category 4, which are deemed to have been reviewed
.
At present, 10 other companies including Qilu Pharmaceutical (Hainan), Zhejiang Huahai Pharmaceutical, Ganli Pharmaceutical Jiangsu, and Shandong Langnuo Pharmaceutical have submitted applications for listing and are under review and approval
.
Data source: the official website of the State Food and Drug Administration, Minaiwang database.
Note: The terminal competition pattern database of Chinese urban physical pharmacies covers physical pharmacies in 293 prefectures and cities across the country (excluding county and rural physical pharmacies), and continuously monitors the entire category Enlarged city physical pharmacy database
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
According to data from Menet.
com, in 2020, the total sales of sitagliptin phosphate tablets at the terminals of China's public medical institutions and the terminals of physical pharmacies in China's cities will exceed 1.
5 billion yuan, and only one company from Merck & Co.
is selling them
.
On August 30, 2021, the drug approval document pending information is released.
Sitagliptin phosphate tablets were developed by Merck.
It is a potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor.
A new type of oral anti-hyperglycemic drug based on the mechanism of incretin hormone is used to improve the blood glucose control of patients with type 2 diabetes
.
Sales of sitagliptin phosphate tablets in Chinese public medical institutions and Chinese urban physical pharmacies (unit: 100 million yuan) Source: Minet.
com database Minet.
com data shows that in recent years, it has been used in urban public hospitals , county-level public hospitals, urban community centers and township hospitals (referred to as the Chinese public medical institutions) terminal and the Chinese cities entity pharmacy sitagliptin phosphate tablets terminal sales of rapid growth, in 2020 a total of more than 1.
5 billion yuan, Merck only one company in sales
.
Sitagliptin phosphate tablets manufacturers include Merck, CSPC Ouyi Pharmaceutical, CP Tianqing Pharmaceutical Group, among which CSPC Ouyi Pharmaceutical, CP Tianqing Pharmaceutical Group, Guangdong Dongyang Sunshine Pharmaceutical Six domestic pharmaceutical companies, including Tonghua Dongbao Pharmaceutical Co.
, Ltd.
, have been approved for imitation of category 4, which are deemed to have been reviewed
.
At present, 10 other companies including Qilu Pharmaceutical (Hainan), Zhejiang Huahai Pharmaceutical, Ganli Pharmaceutical Jiangsu, and Shandong Langnuo Pharmaceutical have submitted applications for listing and are under review and approval
.
Data source: the official website of the State Food and Drug Administration, Minaiwang database.
Note: The terminal competition pattern database of Chinese urban physical pharmacies covers physical pharmacies in 293 prefectures and cities across the country (excluding county and rural physical pharmacies), and continuously monitors the entire category Enlarged city physical pharmacy database
.
The above sales are calculated based on the average retail price of the product at the terminal
.
